IMVARIA Reports Multi-Site Clinical Experience With FDA-Authorized AI Diagnostic Service for Idiopathic Pulmonary Fibrosis at ATS 2025
BERKELEY, Calif.--(BUSINESS WIRE)--May 18, 2025--
IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today reported results from multi-site clinical experiences with IMVARIA's diagnostic referral service, where pulmonologists send cases for AI-supported diagnostic evaluation of suspected Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF). Built by medical doctors with software engineering expertise, Fibresolve is the first ever FDA-authorized AI adjunctive diagnostic service of any type in lung fibrosis. Clinical data from use around the U.S. will be presented by pulmonary experts from Harvard's Mass General Hospital at ATS 2025 International Conference, focusing on respiratory diseases, held on May 16-21, 2025 in San Francisco.
'We're excited that our clinical users are sharing real-world experience with Fibresolve at the ATS Conference,' said Joshua Reicher, MD, Co-founder and CEO of IMVARIA. 'At IMVARIA, we've taken a different approach to AI – one that makes it far easier for pulmonologists to benefit from this new technology without changing workflows or installing complex systems. As practicing medical doctors, my co-founder Dr. Michael Muelly and I designed Fibresolve to meet the highest medical standards, deliver new insights, and make it easy for clinicians to use AI with confidence and minimal burden. We're proud to see that approach working in real clinical settings.'
IMVARIA's Fibresolve received FDA authorization in early 2024 and has gone through a rigorous process to make it useful and reliable for pulmonologists. Fibresolve is available through IMVARIA's centralized service that uses AI to help guide safe, non-invasive diagnoses. Fibresolve also has the distinction as the first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes by the American Medical Association (AMA) in any disease.
IMVARIA is additionally presenting data on ScreenDx and Bronchosolve, two more AI solutions in its pulmonary portfolio. ScreenDx, FDA-cleared in 2025, is the first AI technology authorized to assess interstitial lung findings compatible with ILD. Bronchosolve is an investigational tool designed to support more accurate assessment of indeterminate lung nodules and is currently under research investigation.
Poster Presentations at ATS 2025 Conference
Fibresolve
Title: Clinical Experience with the First FDA-Authorized Artificial Intelligence Tool in Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis
Session: A46 - New Research in Biomarkers and Imaging for ILD
Poster: P1547
Date and Time: Sunday, May 18, 2025: 9:15 AM - 4:15 PM
ScreenDx
Title: Automated Al Detection of Interstitial Lung Disease by Computed Tomography (CT) in the COPDGene Trial; Subanalysis and Characteristics of Accurately Detected Cases
Session: A57 - Late Breaking Abstracts in Clinical Problems
Poster: P1006
Date and Time: Sunday, May 18, 2025: 9:15 AM - 4:15 PM
Bronchosolve
Title: Closed Loop, Full Automation of Suspicious Lung Nodule Risk Assessment with AI in Screening Cases
Session: B110 - The Road to Early Detection: Advancing Lung Cancer Screening Through AI, Risk Models, And Real-World Data
Poster: 619
Date and Time: Monday, May 19, 2025: 2:15 PM - 4:15 PM
Title: Age-Stratified Subanalysis of a Closed Loop, Fully Automated Lung Nodule Risk Assessment Al Software
Session: B80-1 - From Bench to Bedside: Innovative Biomarkers, Screening Approaches, And Personalized Treatments In Lung Cancer
Poster: P804
Date and Time: Monday, May 19, 2025: 9:15 AM - 4:15 PM
Together, these presentations reflect IMVARIA's mission to empower clinicians to make the best decisions through clinically meaningful AI.
For more information about IMVARIA, click here.
About IMVARIA Inc.
IMVARIA is a health tech company pioneering AI-driven solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its AI Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science. IMVARIA is based in Berkeley, CA. For more information, go to www.imvaria.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250518669631/en/
CONTACT: Media Contact
Anthony Petrucci
Bioscribe
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: TECHNOLOGY RESEARCH HEALTH TECHNOLOGY CARDIOLOGY BIOTECHNOLOGY HEALTH GENERAL HEALTH SCIENCE ARTIFICIAL INTELLIGENCE
SOURCE: IMVARIA Inc.
Copyright Business Wire 2025.
PUB: 05/18/2025 10:30 AM/DISC: 05/18/2025 10:29 AM
http://www.businesswire.com/news/home/20250518669631/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
15 minutes ago
- New York Times
Las Vegas agrees two-year Formula One contract extension through 2027
MONTREAL — The Las Vegas Grand Prix will remain part of the Formula One calendar for at least the next two years after officials confirmed they have agreed an extension to cover 2026 and 2027. Las Vegas joined the F1 calendar in 2023 on an initial three-year contract, albeit with a long-term commitment in place from the casino partners and a 10-year approval from Clark County for the race to take place along the Strip. Advertisement Earlier this week, F1 announced the 2026 calendar including Las Vegas despite there being no formal communication about the race being renewed beyond this year. Senior leadership members from casino partners including Wynn, the MGM Grand, Caesars and the Venetian, plus the Las Vegas Convention and Visitors Authority, were in Montreal on Saturday to take part in a media panel discussing the future of the Las Vegas Grand Prix, and referred to an 'extension' being in place. Asked by The Athletic to clarify the contractual status of the grand prix, Emily Prazer, the president of the Las Vegas Grand Prix and chief commercial officer of F1, confirmed that a two-year renewal had been agreed by the various partners. 'We've agreed collectively that we're going to do a two-year extension for 2026 and '27,' Prazer said. 'We want to make sure that we're continuing to evolve what we're doing. But the intent is a much longer-term arrangement. 'As we all know, the race has had its challenges, but we're coming out the other side. So we want to make sure that it continues to work for both sides. 'So collectively, we sat down and agreed that was the best approach. We're very much planning longer-term, but that's kind of where we're at right now.' Steve Hill, the CEO and president of the LVCVA, added: 'The length of extensions don't really reflect anything other than it just makes sense incrementally, we know what's going to happen over the next couple of years. 'We're planning on this being a permanent race, we'll just keep planning extensions that will probably expand as we go forward.' The Las Vegas Grand Prix endured a tricky debut in 2023 amid concerns from fans about ticket and hotel prices, as well as an issue with a loose water valve cover on Thursday night in practice that led to FP1 being cancelled and FP2 being significantly delayed. Advertisement But it ended up being one of the best races of the year with plenty of overtaking, and the track layout proved popular with the drivers, while the high price points were addressed for 2024, including a significant drop in hotel rates. For 2025, officials in Las Vegas have brought forward the start time from its previous slot of 10 p.m. PT on Saturday to 8 p.m. after feedback from both paddock personnel and fans about it being too late to start the race. (Alex Bierensfor Heineken)
Bloomberg
15 minutes ago
- Bloomberg
NASA Considers Launching Astronaut Mission Next Week After Delay
NASA is considering launching its fourth astronaut mission to the International Space Station as early as next Thursday after a repair review caused a delay. NASA has looked into repair efforts for what it described as small leaks in a service module at the ISS. NASA, Axiom Space, and Elon Musk's SpaceX are now reviewing launch opportunities as soon as June 19, it said in a statement.
Forbes
16 minutes ago
- Forbes
New iPhone Warning: Another Phone Will No Longer Receive Support
Friday the 13th has a ring of bad luck to it, and this month, it has brought a change of status to the iPhone XS. As of June 13, that phone is added to its vintage product list. Here's why, and what it means. Apple iPhone XS T3 Magazine/Future via Getty Images Apple adds products to its vintage (and later its obsolete) lists on a strict schedule, shown on a support page. 'Products are considered vintage when Apple stopped distributing them for sale more than 5 and less than 7 years ago,' the company says. The iPhone XS went on sale in September 2018 and though it was discontinued a year later, it was still on sale through select resellers. So, that means it's only just passed the five-year point to reach vintage status, something spotted by Joe Rossignol at MacRumors. This doesn't mean the phone is no longer usable, nor that Apple won't support it — though it's now on a countdown to obsolete, which will mean it's not supported at all. More on that below. For now, you can still get the phone repaired either by an Apple Store or Apple Authorized Service Provider, although this is subject to the continuing availability of parts, and there's no guarantee how long that will be. As for software support, the iPhone XS runs the current software, iOS 18, but it will not be compatible with this fall's update, which is called iOS 26 (as part of a wholesale renaming policy by Apple for the operating systems for all its devices) though the latest iPhone 16 series will be supported. This also doesn't mean it won't receive software updates. Apple routinely releases new updates to the previous OS when the next one launches, primarily for those users who aren't ready to jump on board with the next version. Additionally, it will usually continue with software updates containing security fixes, for instance, for some months after the new OS has taken root. Things change when the iPhone reaches obsolete status, which for the iPhone XS will be in two years' time. 'Products are considered obsolete when Apple stopped distributing them for sale more than 7 years ago… Apple discontinues all hardware service for obsolete products, and service providers cannot order parts for obsolete products,' the company says. For now, though, if you're happy with the iPhone XS, there's no urgent need to switch.
